The FDA has approved AbbVie’s Vyalev, the first 24-hour subcutaneous infusion of levodopa-based therapy for Parkinson’s disease. This groundbreaking treatment offers hope for patients struggling with motor fluctuations and could significantly improve their quality of life. The article also explores the implications of this approval on AbbVie’s stock price and provides insights into its potential future trajectory.